FindTrial
Sign In

A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)

A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221281
Enrollment
Unknown
Registered
2010-10-23
Start date
2010-10-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

investigational material(s) Generic name etc : Ramucirumab DP (IMC-1121B) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Invest

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Child-Pugh score of < 9 (Child-Pugh A or B [B7 or B8]) -BCLC stage C or BCLC B not amenable to locorrectional therapy or refractory to locoregional therapy. -Diagnosis of HCC (excluding fibrolamellar carcinoma) -The patient has received sorafenib as the most recent systemic therapeutic intervention. -Adequate Organ Function

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026